

# DUOLITH® SD1 T-TOP ULTRA

Industry Leading Innovation and Performance for the Treatment  
of Pain Associated with Chronic Proximal Plantar Fasciitis

FDA  
APPROVED

## The Next Generation of ESWT Extracorporeal Shock Wave Treatment with Patented Focused "Cylindrical Source" Technology

Powered by STORZ Medical



**CuraMedix**  
Innovative Technologies for Advanced Healing

# DUOLITH® SD1 T-TOP ULTRA

## ESWT – The Next Generation of Non-Invasive Treatment with Patented Electromagnetic Focused “Cylindrical Source” Technology

The advantage of the new **CuraMedix DUOLITH® SD1 T-TOP ULTRA** device is its time-tested, clinically-proven focused ESWT technology platform, powered by STORZ Medical.

High energy, acoustic pressure waves are delivered in the “shock wave” spectrum, consistently throughout the entire focal zone.

The DuoLith® SD1 T-TOP ULTRA uses an electromagnetically generated shock wave produced within a hand-held applicator (F-SW Handpiece). The shock wave is generated by discharging a high voltage capacitor located in the control unit into a cylindrically shaped coil system in the handpiece which is surrounded by a cylindrical metallic membrane. The transient magnetic field produced by the coil induces eddy currents in the metal membrane, causing it to repel from the coil, producing a pressure wave. The membrane is immersed in water and the pressure wave produced by the membrane propagates through the water to a concentric parabolic reflector, where it is reflected to a focal point outside of the handpiece in front of the reflector.



**With its progressive technological advancements,** Extracorporeal Shock Wave Treatment (ESWT) delivers an evidence-based, non-surgical solution for patients suffering from chronic heel pain. It addresses the increasing demand for patient convenience, less down-time and risk, as well as better clinical and economic outcomes, and improved practice efficiencies and cash-flow.

**DUOLITH® SD1 T-TOP ULTRA Focused ESWT** – a non-invasive treatment for patients with heel pain due to chronic proximal plantar fasciitis.

### Benefits:

- Evidence-based\*
- Improved clinical and economic outcomes
- Non-invasive
- No anesthesia required
- Easy patient application
- High patient satisfaction
- Seamless integration

\*Study: Gollwitzer H et al. Clinically relevant effectiveness of focused extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: a randomized, controlled multicenter study. J Bone Joint Surg Am. 2015 May 6;97(9):701-8. doi: 10.2106/JBJS.M.01331.

### Facts and Figures:

- Powerful and consistent energy range, individually selectable: 0.01 - 0.55 mJ/mm<sup>2</sup>
- Adjustable depth and therapeutic range: 0-125mm
- Large focal zone, increased targeting precision: 5.4 x 5.4mm (at 0.1mJ/mm<sup>2</sup>)
- Frequency range: 1-8 Hz
- Trigger button activation on handpiece
- LCD touch screen-color display
- USB/LAN ports
- All controls integrated into handpiece
- Optional C-ACTOR handpiece with expanded energy range
- Optional 10" touch screen/tablet

**Patient Care Redefined**  
**CuraMedix**  
Innovative Technologies for Advanced Healing

TOLL FREE: 877-699-8399 TEL: 401-333-6500 FAX: 401-633-6565  
INFO@CURAMEDIX.COM • WWW.CURAMEDIX.COM

### Important Information for U.S. Customers:

Certain devices and references made herein to specific indications of use may have not received clearance or approval by the United States Food and Drug Administration. Practitioners in the United States should first consult with their local CuraMedix representative in order to ascertain product availability and specific labeling claims. Federal (USA) law restricts certain devices referenced herein to sale, distribution, and use by, or on the order of a physician, dentist, veterinarian, or other practitioner licensed by the law of the State in which she/he practices to use or order the use of the device.

Caution: Federal law restricts this device to sale by or on the order of a physician.